Regarding “CIN” tumors, they present a characteristic set of mutations on the tumor suppressor gene APC as well as on the proto-oncogene Kirsten RAS (KRAS), activating the initiation and progression signaling pathways of CRC [24]. This evidence concerns the gene KRAS and colorectal carcinoma.